Brokerages expect Davita Inc (NYSE:DVA) to announce $1.66 earnings per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Davita’s earnings, with estimates ranging from $1.42 to $1.75. Davita posted earnings of $0.90 per share in the same quarter last year, which would suggest a positive year over year growth rate of 84.4%. The firm is scheduled to announce its next earnings results on Wednesday, February 12th.
According to Zacks, analysts expect that Davita will report full year earnings of $5.31 per share for the current year, with EPS estimates ranging from $5.24 to $5.38. For the next fiscal year, analysts anticipate that the business will post earnings of $5.56 per share, with EPS estimates ranging from $5.42 to $5.87. Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Davita.
Davita (NYSE:DVA) last posted its earnings results on Tuesday, November 5th. The company reported $1.53 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.29. Davita had a net margin of 3.68% and a return on equity of 19.95%. The firm had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter last year, the company earned $0.56 earnings per share. The company’s revenue was up 2.0% on a year-over-year basis.
A number of research firms recently weighed in on DVA. SunTrust Banks lifted their price objective on shares of Davita to $72.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Wolfe Research lowered Davita from an “outperform” rating to a “market perform” rating and set a $57.00 price target for the company. in a report on Friday, October 25th. Raymond James cut Davita from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. UBS Group decreased their price objective on Davita from $61.00 to $60.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Finally, Sanford C. Bernstein started coverage on Davita in a report on Tuesday, November 12th. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $65.00.
DVA traded up $0.19 on Friday, hitting $72.70. The company’s stock had a trading volume of 1,821,749 shares, compared to its average volume of 2,078,820. The company’s 50 day simple moving average is $66.47 and its 200-day simple moving average is $58.15. The firm has a market cap of $9.43 billion, a P/E ratio of 20.36, a price-to-earnings-growth ratio of 0.59 and a beta of 1.67. Davita has a 12 month low of $43.40 and a 12 month high of $73.50. The company has a quick ratio of 1.77, a current ratio of 1.81 and a debt-to-equity ratio of 4.26.
A number of institutional investors have recently bought and sold shares of DVA. Flinton Capital Management LLC increased its holdings in shares of Davita by 3.3% in the second quarter. Flinton Capital Management LLC now owns 187,884 shares of the company’s stock worth $10,571,000 after purchasing an additional 6,052 shares during the period. Sciencast Management LP bought a new position in Davita in the 3rd quarter worth about $1,017,000. Wedge Capital Management L L P NC increased its stake in Davita by 28.8% in the 2nd quarter. Wedge Capital Management L L P NC now owns 37,691 shares of the company’s stock worth $2,120,000 after acquiring an additional 8,434 shares during the last quarter. Tibra Equities Europe Ltd purchased a new stake in shares of Davita in the 3rd quarter valued at about $1,141,000. Finally, Bank of Hawaii purchased a new stake in shares of Davita in the 3rd quarter valued at about $430,000. 94.41% of the stock is currently owned by institutional investors and hedge funds.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading: Investing in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.